The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Prevention of Transition From Incipient to Overt Nephropathy With Telmisartan in Patients With Type 2 Diabetes
Abstract
To date, evidence for long-term renoprotection with angiotensin receptor blockers (ARBs) has come almost exclusively from Caucasian patients (1–3), despite Japanese people being at high risk of diabetic nephropathy and very susceptible to end-stage renal disease (4–6). We conducted the INNOVATION Study (Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy) to evaluate the efficacy of an ARB in preventing transition from microalbuminuria to overt nephropathy in Japanese patients (7). This study is the first large-scale clinical study to investigate prevention of overt diabetic nephropathy using an ARB in normotensive and hypertensive Japanese patients with type 2 diabetes. The randomized, multicenter, double-blind, placebo-controlled trial was performed in patients aged from 30 to 74 years with type 2 diabetes and urinary albumin-to-creatinine ratio (UACR) 100–300 mg/g and serum creatinine <1.5 mg/dl (men) and <1.3 mg/dl (women). Exclusion criteria included type 1 diabetes, age of diabetes onset <30 years, seated systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥180/100 mmHg, and definable chronic kidney disease …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this trial, telmisartan also signi fi cantly reduced blood pressure levels.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [12]
In the citing paper
“In the INNOVATION trial, the ARB telmisartan was associated with a lower transition rate to overt nephropathy than placebo after 1 year of follow-up.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [12]
In the citing paper
“suggesting that use of RAS blockade may be bene fi cial in patients without hypertension. 12,14”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [12]
In the citing paper
“However, after adjustment for the difference in blood pressure levels between the placebo and treatment groups, the bene fi cial effect of telmisartan in delaying progression to overt nephropathy persisted.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [12]
In the citing paper
“The CREDENCE, DAPA-CKD, and EMPA-KIDNEY placebo-controlled trials were all stopped early for efficacy while testing canagliflozin, dapagliflozin, and empagliflozin, respectively.153,543,711”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [711]
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Progression, remission, regression of chronic renal diseases
Ruggenenti, P., Schieppati, A., & Remuzzi, G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04728-0 · Cited by 554
An Overview of Regular Dialysis Treatment in Japan (as of 31 December 2001)1
Patient Registration Committee, J. S. F. D. T. (2004) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1526-0968.2004.00109.x · Cited by 68
Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., & Katayama, S. (2005) · Journal of International Medical Research · doi:10.1177/147323000503300610 · Cited by 32
Self-citationHollenberg, N. K. (2001) · Current Hypertension Reports · doi:10.1007/s11906-001-0035-5 · Cited by 8
Cited by
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
on behalf of The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension, Ogihara, T., Kikuchi, K., Matsuoka, H., Fujita, T., Higaki, J., Horiuchi, M., Imai, Y., Imaizumi, T., Ito, S., et al. (2014) · Hypertension Research · doi:10.1038/hr.2014.68 · Cited by 1,385
Self-citationKDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Metadata
- Authors
- Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., Katayama, S., & for the INNOVATION Study Group
- Affiliations
- Okayama University (JP)
- Asahikawa Medical University (JP)
- Tokyo Women's Medical University (JP)
- Kitasato University (JP)
- Tohoku University (JP)
- Juntendo University (JP)
- Saitama Medical University (JP)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-06-01
- Volume
- 30
- Issue
- 6
- Pages
- 1577-1578
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2140563977
- Cited by
- 230
- References
- 8
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 5 · 2023: 14 · 2022: 8 · 2021: 8 · 2020: 12 · 2019: 3 · 2018: 7 · 2017: 11 · 2016: 8 · 2015: 14 · 2014: 14 · 2013: 17 · 2012: 21
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Keywords
- telmisartan, angiotensin receptor blockers, diabetic nephropathy, type 2 diabetes, microalbuminuria, renal protection, Japanese patients, hypertension, albumin-creatinine ratio
- MeSH terms
- Telmisartan, Adult, Aged, Albuminuria, Angiotensin-Converting Enzyme Inhibitors, Benzimidazoles, Benzoates, Diabetic Nephropathies, Double-Blind Method, Humans, Middle Aged, Placebos
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of Transition From Incipient to Overt Nephropathy With Telmisartan in Patients With Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/dc06-1998
- The paper
- Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., Katayama, S., & for the INNOVATION Study Group. (2007). Prevention of Transition From Incipient to Overt Nephropathy With Telmisartan in Patients With Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/dc06-1998
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.